Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Pandemics and Biosecurity
3OCT

Bundibugyo Ebola: 831 cases, 186 dead

3 min read
13:42UTC

WHO's Disease Outbreak News 603 logged 831 cases and 186 deaths from Bundibugyo Ebola on 21 May, a tripling in four days that owes more to counting than to spread.

ScienceDeveloping
Key takeaway

A 24% fatality rate measured against 21% contact tracing is a floor, not a measurement of the outbreak's true severity.

WHO's Disease Outbreak News 603, published 21 May, recorded 831 total cases (85 confirmed, 746 suspected) and 186 deaths from Bundibugyo Ebola in the Democratic Republic of Congo (DRC)⁠1. That is roughly triple the 246 cases on the books when WHO Director-General Tedros Adhanom Ghebreyesus declared the Public Health Emergency of International Concern (PHEIC) four days earlier, the first such declaration ever made for this Ebola species. Bundibugyo is one of six Ebola virus species, with no licensed vaccine or treatment of its own.

Read the jump with care. Most of the rise is case-finding catching up after the declaration, not the virus accelerating. The outbreak ran undetected in Ituri province for more than four weeks, so surveillance teams are now logging deaths that occurred before anyone was looking, rather than recording a sudden burst of new infections.

The suspected case-fatality rate sits near 24%, with 96% of cases in three Ituri health zones: Mongbwalu, Rwampara and Bunia⁠2. The figure that should worry a reader more is the 21% contact follow-up rate: insecurity keeps tracing teams away from most named contacts⁠3. A 24% fatality rate measured against a 21% tracing rate is a partial count of a poorly observed outbreak, not a settled verdict on how lethal it is.

The sharpest signal is at Mongbwalu General Referral Hospital, where four healthcare workers died in four days⁠4. Clustered staff deaths point to a breakdown in infection prevention and control, the gowning, isolation and barrier-nursing routines that stop Ebola spreading inside the hospitals treating it. Hospital amplification of this kind turned the 2014 West Africa outbreak from regional to catastrophic; when the people running isolation wards begin dying, the wards stop being safe.

Deep Analysis

In plain English

Bundibugyo (bun-dee-BOO-gyo) ebolavirus is one of six known Ebola species. It had only 169 recorded cases in its entire history before this year. There are no approved vaccines or treatments for Bundibugyo; the medicines that worked in previous DRC Ebola outbreaks target a different species and do not work here. The jump from 246 cases to 831 in four days is partly alarming and partly explained: when the WHO declared a global health emergency, more health workers started looking. But four hospital staff dying in four days at one facility in Mongbwalu, a gold-mining town in northeastern DRC, shows the virus has found its way into a hospital where protective equipment and isolation rooms are sparse. Only one in five known contacts is being monitored, because armed groups control the roads into many affected areas.

Deep Analysis
Root Causes

Ituri Province's gold-mining economy drives constant cross-border population movement between DRC, Uganda and South Sudan through informal routes that bypass formal health checkpoints. The Djugu and Irumu territories at the outbreak core have experienced persistent armed conflict involving the ADF (Allied Democratic Forces) and CODECO militia, which physically prevents contact tracers from operating. That is why contact follow-up stands at 21% despite a PHEIC declaration.

Bundibugyo ebolavirus had only 169 combined cases across two prior outbreaks before 2026, meaning clinical staff in Ituri had no institutional memory of managing it. The four-week undetected silent phase meant the outbreak was already seeded across three health zones before isolation protocols were triggered, creating the nosocomial amplification the DON603 figures capture.

What could happen next?
  • Risk

    If Mongbwalu General Referral Hospital cannot be stabilised as an IPC environment, the nosocomial chain will seed additional health zones as patients seek care at facilities with no Bundibugyo protocol.

  • Consequence

    The 21% contact follow-up rate means the outbreak model cannot reliably estimate R-effective; containment decisions are being made on incomplete transmission data.

First Reported In

Update #4 · Ebola triples, response misfires

World Health Organization· 24 May 2026
Read original →
Different Perspectives
IGWG co-chair Tovar da Silva Nunes
IGWG co-chair Tovar da Silva Nunes
The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.
Fraport
Fraport
The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.
European Centre for Disease Prevention and Control
European Centre for Disease Prevention and Control
ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.
Pan American Health Organization
Pan American Health Organization
PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.
Bangladesh Directorate General of Health Services
Bangladesh Directorate General of Health Services
The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.
Minapharm
Minapharm
The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.